瑞舒伐他汀联合厄贝沙坦治疗老年原发性高血压肾病的效果  

Clinical Trial of Rosuvastatin Combined with Irbesartan in the Treatment of Elderly Primary Hypertension Nephropathy

作　　者：朱美松[1] 丁娟[1] 赵大奎[1] ZHU Meisong;DING Juan;ZHAO Dakui(Cancer Hospital of Anhui Huainan Oriental Hospital Group,Huainan 232000,China)

机构地区：[1]安徽淮南东方医院集团肿瘤医院,安徽淮南232000

出　　处：《中外医学研究》2021年第7期42-44,共3页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：目的:观察瑞舒伐他汀联合厄贝沙坦治疗老年原发性高血压肾病患者的临床效果。方法:选取2018年9月-2019年11月本院收治的66例老年原发性高血压肾病患者,随机平均分为对照组和试验组,每组33例。对照组给予厄贝沙坦口服治疗,试验组在对照组治疗的基础上,给予瑞舒伐他汀钙口服治疗。对比两组治疗前、治疗6个月后血压指标、实验室指标、肾功能指标、临床有效率及不良反应发生情况。结果:两组患者治疗前血压指标、实验室指标、肾功能指标,差异无统计学意义(P>0.05),治疗6个月后,两组患者的收缩压、舒张压、超敏C反应蛋白、胱抑素C、24 h尿蛋白定量比治疗前均明显降低,差异有统计学意义(P<0.05),两组患者血清肌酐治疗前后比较差异无统计学意义(P>0.05),试验组超敏C反应蛋白、胱抑素C水平低于对照组,差异有统计学意义(P<0.05),两组临床总有效率、不良反应发生率比较,差异无统计学意义(P>0.05)。结论:瑞舒伐他汀联合厄贝沙坦治疗老年原发性高血压肾病可有效降低血压、超敏C反应蛋白、胱抑素C、24 h尿蛋白定量水平,优于单独使用厄贝沙坦,临床值得推广。Objective:To observe the clinical efficacy of Rosuvastatin combined with Irbesartan in the treatment of elderly primary hypertension nephropathy patients.Method:A total of 66 elderly primary hypertension nephropathy from September 2018 to November 2019 in our hospital were selected and randomly divided into the control group and the experimental groups,with 33 cases in each group.The control group was given oral treatment with Irbesartan,and the experimental group was given oral treatment with Rosuvastatin Calcium based on the treatment of the control group.The blood pressure indicators,laboratory indicators,renal function indicators,clinical effective rates and adverse reactions were compared between the two groups before treatment and after 6 months of treatment.Result:There was no significant difference in blood pressure,laboratory and renal function indexes between the two groups of patients before treatment(P>0.05).After 6 months of treatment,the systolic blood pressure,diastolic blood pressure,high sensitivity C-reactive protein,Cystatin C and 24 h urine protein quantification were significantly lower than before treatment,and the differences were statistically significant(P<0.05).There was no significant difference in serum creatinine between the two groups before and after treatment(P>0.05).The high sensitivity C-reaction protein and cystatin C levels of the experimental group were greater than those of the control group,and the differences were statistically significant(P<0.05).The clinical total effective rate and the incidence of adverse reactions were basically the same in the two groups,and the differences were not statistically significant(P>0.05).Conclusion:Rosuvastatin combined with Irbesartan can effectively reduce blood pressure,high sensitivity C-reactive protein,cystatin C,24 h urine protein quantitative level in the treatment of elderly primary hypertension nephropathy,which is better than Irbesartan alone.It is worth promoting.

关 键 词：原发性高血压肾病 瑞舒伐他汀 厄贝沙坦 有效性 安全性 

分 类 号：R692[医药卫生—泌尿科学] R544.11[医药卫生—外科学]